Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19
A. Vitelli, S. Capone, A. Raggioli, M. Gentile, S. Battella, A. Lahm, A. Sommella, A. M. Contino, R. A. Urbanowicz, R. Scala, F. Barra, A. Leuzzi, E. Lilli, G. Miselli, A. Noto, , S. Colloca
This paper evaluates a gorilla adenovirus vaccine candidate for COVID-19, showing it is immunogenic in mice and macaques and supports its advancement to a Phase I clinical trial.
bioRxiv · Oct 22, 2020Immunology